Inspira Technologies Introduces Personalized Blood Lab Testing with HYLA Technology

Inspira Technologies Expands HYLA Blood Sensor Technology

In an innovative move, Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) announced the expansion of its cutting-edge HYLA blood sensor technology into a personalized blood lab testing platform. This development promises to facilitate rapid detection of serious medical conditions, providing crucial support in emergency medical settings.

The HYLA technology aims to transform how blood tests are conducted, particularly in hospitals. Traditionally, nurses take periodic blood samples from patients, which can be time-consuming and cumbersome, especially during extracorporeal procedures. With the introduction of the HYLA sensor, blood work can now be conducted in real-time. This means that medical professionals can analyze a patient’s blood condition without the need for conventional blood samples. Such a shift in approach is expected to significantly reduce the workload on hospital staff, as well as cut costs associated with blood sample collection and analysis.

The HYLA blood sensor is designed to be implemented directly near a patient’s bedside—ideal for use in emergency rooms, intensive care units, and operating rooms. This localized testing could potentially eliminate the need for expensive lab equipment and centralized labs, which often delay diagnosis due to distance and processing time. Inspira's innovative technology may also reduce the number of unnecessary tests performed each year, minimizing the time lost between ordering a test and receiving the results, directly impacting patient care and outcomes.

Currently, HYLA technology is undergoing clinical trials at Sheba Hospital, ranked as one of the world's top hospitals. These trials involve patients undergoing open-heart procedures. The results from these clinical evaluations are highly anticipated, as they will inform the company’s planned submission to the U.S. Food and Drug Administration (FDA) for approval in 2025.

Dagi Ben-Noon, CEO of Inspira Technologies, stated, "Our aim with the HYLA blood sensor technology is to streamline the blood testing process, which is a critical component of patient management. By eliminating the need for physical samples, we enhance the efficiency of medical care and support healthcare professionals in making rapid, informed decisions."

Moreover, the HYLA technology is integrated with Inspira's Augmented Respiration Technology (INSPIRA™ ART), a pioneering device in the life support sector. This integrated system promises to enhance patient monitoring by providing continuous, real-time feedback on a patient’s blood condition, allowing for immediate medical intervention when necessary, thereby improving overall patient care.

With 20 million intensive care unit patients facing acute respiratory failure each year, the combination of INSPIRA ART and HYLA technology has the potential to revolutionize mechanical ventilation. This innovation aligns with Inspira Technologies' mission to improve life-support mechanisms while maintaining patient comfort and stability during treatment.

Inspiring change in medical technology is no small task. Inspira Technologies aims to set new standards in the industry through continuous research, clinical evaluation, and technological advancements. The company has made significant strides with its flagship products and technologies, working diligently toward regulatory approvals while exploring the full capabilities of its innovations in real-world medical settings.

For those interested in the latest breakthroughs in medical technology, Inspira Technologies stands out as a company to watch. With plans for broader clinical evaluations and innovative product releases in the near future, the impact of the HYLA technology could be substantial in the field of personalized medicine and emergency care.

To learn more about Inspira Technologies and its offerings, visit Inspira Technologies website.